BSE filing, BSE: 539574. Summary written from the filing by ALFA Finder's alert engine.
More from Sunshine Capital Ltd
All →Sunshine Capital Q4 FY26 Results: Net Loss of ₹0.1 Cr, Loss Narrows
Sunshine Capital Ltd reported revenue from operations of ₹1 Cr and a net loss of ₹0.1 Cr for Q4 FY26.
- Key figure
- Net loss ₹0.1 Cr
Sunshine Capital Board Meeting Date
Sunshine Capital scheduled a board meeting for May 23, 2026, to approve audited financial results. Trading window remains closed until 48 hours post-declaration.
Sunshine Capital Other Announcement
Sunshine Capital Ltd confirmed it does not meet SEBI's Large Corporate criteria for FY 2025-26. The company remains exempt from mandatory incremental debt-raising requirements.
Sunshine Capital Capacity Expansion
Sunshine Capital Limited is shifting its Corporate Office from Paharganj to its registered address in Rajendra Place, New Delhi, effective May 1, 2026. This administrative move consolidates the company's corporate and registered office operations at a single location where its books of accounts are maintained.
Sunshine Capital Capacity Expansion
Sunshine Capital Limited has shifted its corporate office from Paharganj to Rajendra Place, New Delhi. The new location will serve as both the registered and corporate office to centralize management and administration. Managing Director Surendra Kumar Jain has been authorized to oversee the transition and execute necessary lease agreements.
Sunshine Capital Debt & Borrowing
Sunshine Capital Limited confirmed it does not meet the criteria for a 'Large Corporate' under SEBI's debt-raising framework for FY 2025-26. The company reported zero outstanding borrowings as of the relevant reporting date. This regulatory disclosure maintains transparency regarding the firm's capital structure and future debt-sourcing requirements.
Other financial results announcements
All →Strides Pharma Science Q2 FY27 Results: Net Profit ₹134.1 Cr, Up 2.0% YoY
Strides Pharma Science Ltd reported revenue from operations of ₹1,430 Cr (+17.1% YoY) and net profit of ₹134.1 Cr (+2.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹134.1 Cr · +2.0% YoY
Fusion Klassroom Edutech H1 FY27 Results: Net Profit ₹4.8 Cr, Up 23.1% YoY
Fusion Klassroom Edutech Ltd reported revenue from operations of ₹14.9 Cr (+21.1% YoY) and net profit of ₹4.8 Cr (+23.1% YoY) for H1 FY27.
- Key figure
- Net profit ₹4.8 Cr · +23.1% YoY
Deepak Nitrite Q2 FY27 Results: Net Profit ₹397.7 Cr, Up 234.8% YoY
Deepak Nitrite Ltd reported revenue from operations of ₹3,076 Cr (+61.8% YoY) and net profit of ₹397.7 Cr (+234.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹397.7 Cr · +234.8% YoY
Asset Reconstruction Company (India) Q2 FY27 Results: Net Profit ₹157.8 Cr, Up 55.8% YoY
Asset Reconstruction Company (India) Ltd reported revenue from operations of ₹276.5 Cr (+30.7% YoY) and net profit of ₹157.8 Cr (+55.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹157.8 Cr · +55.8% YoY
Capital Small Finance Bank Q2 FY27 Results: Net Profit ₹45.6 Cr, Up 30.7% YoY
Capital Small Finance Bank Ltd reported revenue from operations of ₹300.8 Cr (+17.3% YoY) and net profit of ₹45.6 Cr (+30.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹45.6 Cr · +30.7% YoY
Sanofi India Q2 FY27 Results: Net Profit ₹116.7 Cr, Up 53.6% YoY
Sanofi India reported unaudited Q3 and nine-month results to 30 September 2026, with profit before tax up 22% to INR 158 crore. It also declared an interim dividend of Rs 75 per share with a record date of 5 November 2026.
- Key figure
- Net profit ₹116.7 Cr · +53.6% YoY